Clinical Trial Update: Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing stereotactic body radiotherapy with concurrent pembrolizumab for metastatic urothelial carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Metastatic Urothelial Cancer | Phase 1 | Status: COMPLETED